Artivion, Inc. Stock News

Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.03 per share a year ago.

Artivion, Inc. has begun to recover from the fallout after its PROACT trial failure. On-X sales almost doubled the 5-year average range in Q1, and management look to 15% CAGR in sales moving forward.

Artivion, Inc. (NYSE:AORT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President, Gilmartin Group Pat Mackin - Chief Executive Officer Ashley Le

ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial result

Artivion: Reaffirm Hold As Pressures To Growth Remain.

There's nothing like an upside earnings surprise to juice the price of a company's shares.

Artivion, Inc. (NYSE:AORT ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President at Gilmartin Group Pat Mackin - Chairman, President & CEO

Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 fi

Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Artivion, Inc. (NYSE:AORT ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sam Bentzinger - Gilmartin Group Pat Mackin - Chairman, President & CEO Ashley Lee - EVP &

Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Artivion, Inc.'s decision to pull the PROACT Xa trial resulted in heavy downside for the share price. Investors have sold positions rapidly such that the stock trades at multi-year lows.

ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deu

ATLANTA , Sept. 6, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming